Welcome to our dedicated page for Centessa Pharmaceuticals plc American Depositary Shares news (Ticker: CNTA), a resource for investors and traders seeking the latest updates and insights on Centessa Pharmaceuticals plc American Depositary Shares stock.
Centessa Pharmaceuticals plc (NASDAQ: CNTA) is a next-generation biopharmaceutical company based in Cambridge, Massachusetts, dedicated to transforming the traditional drug development model. By leveraging an asset-centric R&D approach at scale, Centessa is advancing a robust pipeline of highly validated programs led by industry-leading teams. Each program is managed by a Centessa subsidiary and supported by a centralized infrastructure and executive management team.
The company’s clinical-stage assets include:
- SerpinPC - A novel treatment for Hemophilia A and B, currently in Phase 2b trials. SerpinPC is a subcutaneously administered inhibitor of APC, aiming to provide effective treatment irrespective of severity or inhibitor status.
- LB101 - A cutting-edge PD-L1xCD47 LockBody, targeting solid tumors. LB101 is currently in a Phase 1/2a clinical trial, designed to selectively drive potent effector functions to the tumor micro-environment while minimizing systemic toxicity.
- ORX750 - An orally administered, highly selective orexin receptor 2 (OX2R) agonist for Narcolepsy Type 1 (NT1) and other sleep disorders, currently in its Phase 1 clinical study.
- MGX292 - Targeting Pulmonary Arterial Hypertension (PAH).
- Undisclosed programs targeting solid tumors.
Recent Achievements include:
- Phase 2b study PRESent-3 of SerpinPC showing promising preliminary results.
- FDA Fast Track designation for SerpinPC in treating Hemophilia B.
- Progress in LB101's Phase 1/2a clinical trial.
- Launch of the Phase 1 study for ORX750, with initial proof-of-concept data in sleep-deprived healthy volunteers expected later this year.
Centessa’s innovative approach and comprehensive pipeline aim to deliver transformational medicines to patients, setting a new standard of care. For more information, visit their official website at http://www.centessa.com/.
Centessa Pharmaceuticals (Nasdaq: CNTA) announced its participation in upcoming investor conferences. Members of its management team will present at the Jefferies Global Healthcare Conference on June 6, 2024, in New York, NY, and at the Goldman Sachs 45th Annual Global Healthcare Conference on June 11, 2024, in Miami, FL. Participants can access live webcasts and archived recordings of these events through the company's investor relations website.
Centessa Pharmaceuticals (Nasdaq: CNTA) reported its Q1 2024 financial results and business highlights. Key updates include the initiation of a Phase 1 clinical trial for ORX750, an orexin receptor 2 agonist for narcolepsy, and ongoing registrational studies for SerpinPC in hemophilia B. The company completed a public offering, raising $107.2 million, extending its cash runway to mid-2026. Financially, Centessa reported a net loss of $38 million for Q1 2024, down from $50.7 million in Q1 2023. R&D and administrative expenses also saw reductions, with R&D at $22.7 million and G&A at $13.4 million.
FAQ
What is the current stock price of Centessa Pharmaceuticals plc American Depositary Shares (CNTA)?
What is the market cap of Centessa Pharmaceuticals plc American Depositary Shares (CNTA)?
What does Centessa Pharmaceuticals specialize in?
Where is Centessa Pharmaceuticals headquartered?
What is SerpinPC?
What stage is LB101 in?
What is the focus of ORX750?
Has SerpinPC received any special designations?
What kind of development model does Centessa Pharmaceuticals use?
What other programs are in Centessa's pipeline?
What recent achievements has Centessa Pharmaceuticals made?
How can I find more information about Centessa Pharmaceuticals?
